Non-small Cell Lung Cancer
Conditions
Keywords
Vedio-assisted thoracoscopic lobectomy, Thoracotomy lobectomy, Real-world evidences;, pN2 NSCLC
Brief summary
The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer
Detailed description
The is a multi-center retrospective study. Patients with pathologic N2 NSCLC who underwent VATS or open lobectomy between 2014 and 2017 were included into this study. Clinical data on patient demographic, clinical characteristics, treatment and clinical outcomes will be collected to evaluate the safety and effectiveness of video-assisted thoracoscopic lobectomy for pathologic N2 NSCLC.
Interventions
PROCEDUREVATS lobectomy
Patients who received lobectomy by video-assisted thoracoscopic surgery
PROCEDUREThoracotomy lobectomy
Patients who received lobectomy by thoracotomy
Sponsors
LinkDoc Technology (Beijing) Co. Ltd.
Tang-Du Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with age \> 18 years old; * Patients with pathologically diagnosed non-small cell lung cancer; * Patients underwent lobectomy by either VATS or thoracotomy between 2014 and 2017; * Patients who received lymphadenectomy for all accessible lymph nodes; * Patients with N2 lymph nodes (+) after surgeries;
Exclusion criteria
* Patients with second primary tumors or multiple primary tumors; * Patients who received chest surgeries before hospitalization; * Patients with superior pulmonary sulcus tumor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 2014-2018 | Overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of hospital stay [Perioperative outcomes] | 2014-2017 | Duration of hospital stay \[Perioperative outcomes\] |
| Postoperative 30 and 90 days [Perioperative outcomes] | 2014-2017 | Postoperative 30 and 90 days \[Perioperative outcomes\] |
| Drainage time [Perioperative outcomes] | 2014-2017 | Drainage time \[Perioperative outcomes\] |
| Intraoperative blood loss [Perioperative outcomes] | 2014-2017 | Intraoperative blood loss \[Perioperative outcomes\] |
| Postoperative complications [Perioperative outcomes] | 2014-2017 | Postoperative complications \[Perioperative outcomes\] |
Other
| Measure | Time frame | Description |
|---|---|---|
| Propensity score matching analysis of perioperative outcomes | 2014-2018 | Propensity score matching analysis of perioperative outcomes |
| Overall survivals in the subgroups stratified by T staging | 2014-2018 | Overall survivals in the subgroups stratified by T staging |
| Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days | 2014-2018 | Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days |
| Propensity score matching analysis of impact factors for overall survival | 2014-2018 | Propensity score matching analysis of impact factors for overall survival |
| Overall survivals in the subgroups stratified by neoadjuvant therapy | 2014-2018 | Overall survivals in the subgroups stratified by neoadjuvant therapy |
| Overall survivals in the subgroups stratified by number of lymph node station involved | 2014-2018 | Overall survivals in the subgroups stratified by number of lymph node station involved |
| Impact factors for overall survival | 2014-2018 | Impact factors for overall survival |
| Impact factors for postoperative mortality within 30/90 days | 2014-2017 | Impact factors for postoperative mortality within 30/90 days |
| Propensity score matching analysis of overall survival | 2014-2018 | Propensity score matching analysis of overall survival |
Countries
China
Outcome results
None listed